 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| Trial completion date, Trial suspension, Trial primary completion date: EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov) - Oct 2, 2024
P1/2, N=18, Suspended, Sponsor: Xinqiao Hospital of Chongqing
Trial completion date: Jan 2024 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Jan 2024 --> Dec 2024
- ||| Trial completion date, Trial suspension, Trial primary completion date, Metastases: EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma (clinicaltrials.gov) - Oct 1, 2024
P1/2, N=20, Suspended, Sponsor: Xinqiao Hospital of Chongqing
Trial completion date: Jan 2024 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Jan 2024 --> Dec 2024 Trial completion date: Aug 2023 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Aug 2023 --> Dec 2024
- TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial. (On Demand | Hall A; Poster Bd # 39) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3823;
P1/2
Initial results from this ongoing study indicate that EBV proteins may be safe and effective TCR-T targets to achieve superior outcomes in advanced EBV-positive NPC patients. Clinical trial information: NCT04139057.
- || Enrollment open, Trial primary completion date, Metastases: EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma (clinicaltrials.gov) - Feb 24, 2023
P1/2, N=20, Recruiting, Sponsor: Xinqiao Hospital of Chongqing
Clinical trial information: NCT04139057. Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2021 --> Aug 2023
- | Trial completion date, Trial primary completion date: EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov) - Feb 15, 2023
P1/2, N=18, Recruiting, Sponsor: Xinqiao Hospital of Chongqing
Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2021 --> Aug 2023 Trial completion date: Feb 2022 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Jan 2024
- | Trial primary completion date: EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov) - Jul 1, 2020
P1/2, N=9, Recruiting, Sponsor: Xinqiao Hospital of Chongqing
Trial completion date: Feb 2022 --> Jan 2024 | Trial primary completion date: Feb 2022 --> Jan 2024 Trial primary completion date: Feb 2020 --> Feb 2022
- | New P1/2 trial: EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC (clinicaltrials.gov) - Oct 24, 2019
P1/2, N=9, Recruiting, Sponsor: Xinqiao Hospital of Chongqing